179 related articles for article (PubMed ID: 19933802)
21. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
22. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.
Morrissey I; Seifert H; Canton R; Nordmann P; Stefani S; Macgowan A; Janes R; Knight D;
J Antimicrob Chemother; 2013 Jan; 68(1):164-7. PubMed ID: 22941898
[TBL] [Abstract][Full Text] [Related]
23. Glycopeptide carboxamides active against vancomycin-resistant enterococci.
Zweifel MJ; Snyder NJ; Cooper RD; Nicas TI; Mullen DL; Butler TF; Rodriguez MJ
J Antibiot (Tokyo); 2003 Mar; 56(3):289-95. PubMed ID: 12760685
[TBL] [Abstract][Full Text] [Related]
24. Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus.
Maki H; Miura K; Yamano Y
Antimicrob Agents Chemother; 2001 Jun; 45(6):1823-7. PubMed ID: 11353632
[TBL] [Abstract][Full Text] [Related]
25. Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci.
Arthur M; Depardieu F; Reynolds P; Courvalin P
Mol Microbiol; 1996 Jul; 21(1):33-44. PubMed ID: 8843432
[TBL] [Abstract][Full Text] [Related]
26. Staphylococcus aureus VRSA-11B is a constitutive vancomycin-resistant mutant of vancomycin-dependent VRSA-11A.
Périchon B; Courvalin P
Antimicrob Agents Chemother; 2012 Sep; 56(9):4693-6. PubMed ID: 22710116
[TBL] [Abstract][Full Text] [Related]
27. Glycopeptide resistance in Staphylococcus aureus: is it a real threat?
Gemmell CG
J Infect Chemother; 2004 Apr; 10(2):69-75. PubMed ID: 15160298
[TBL] [Abstract][Full Text] [Related]
28. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.
Münch D; Engels I; Müller A; Reder-Christ K; Falkenstein-Paul H; Bierbaum G; Grein F; Bendas G; Sahl HG; Schneider T
Antimicrob Agents Chemother; 2015 Feb; 59(2):772-81. PubMed ID: 25403671
[TBL] [Abstract][Full Text] [Related]
29. Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.
Zeng D; Debabov D; Hartsell TL; Cano RJ; Adams S; Schuyler JA; McMillan R; Pace JL
Cold Spring Harb Perspect Med; 2016 Dec; 6(12):. PubMed ID: 27663982
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms of vancomycin resistance.
Stogios PJ; Savchenko A
Protein Sci; 2020 Mar; 29(3):654-669. PubMed ID: 31899563
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel protein synthesis inhibitor active against gram-positive bacteria.
Eibergen NR; Im I; Patel NY; Hergenrother PJ
Chembiochem; 2012 Mar; 13(4):574-83, 490. PubMed ID: 22362659
[TBL] [Abstract][Full Text] [Related]
32. Significant increase in the isolation of glycopeptide-resistant enterococci from patients hospitalized in the transplant surgery ward in 2004-2005.
Młynarczyk G; Grzybowska W; Młynarczyk A; Tyski S; Kawecki D; Łuczak M; Chmura A; Rowiński W
Transplant Proc; 2007 Nov; 39(9):2883-5. PubMed ID: 18022008
[TBL] [Abstract][Full Text] [Related]
33. Pursuit of next-generation glycopeptides: a journey with vancomycin.
Acharya Y; Dhanda G; Sarkar P; Haldar J
Chem Commun (Camb); 2022 Feb; 58(12):1881-1897. PubMed ID: 35043130
[TBL] [Abstract][Full Text] [Related]
34. Selective cleavage of D-Ala-D-Lac by small molecules: re-sensitizing resistant bacteria to vancomycin.
Chiosis G; Boneca IG
Science; 2001 Aug; 293(5534):1484-7. PubMed ID: 11520986
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology and mechanisms of glycopeptide resistance in enterococci.
Zirakzadeh A; Patel R
Curr Opin Infect Dis; 2005 Dec; 18(6):507-12. PubMed ID: 16258324
[TBL] [Abstract][Full Text] [Related]
36. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Brumfitt W; Salton MR; Hamilton-Miller JM
J Antimicrob Chemother; 2002 Nov; 50(5):731-4. PubMed ID: 12407132
[TBL] [Abstract][Full Text] [Related]
37. Elucidation of the active conformation of vancomycin dimers with antibacterial activity against vancomycin-resistant bacteria.
Nakamura J; Yamashiro H; Hayashi S; Yamamoto M; Miura K; Xu S; Doi T; Maki H; Yoshida O; Arimoto H
Chemistry; 2012 Oct; 18(40):12681-9. PubMed ID: 22915313
[TBL] [Abstract][Full Text] [Related]
38. Glycopeptide resistant Staphylococcus.
Witte W
J Vet Med B Infect Dis Vet Public Health; 2004; 51(8-9):370-3. PubMed ID: 15525368
[TBL] [Abstract][Full Text] [Related]
39. Cold Stress Makes Escherichia coli Susceptible to Glycopeptide Antibiotics by Altering Outer Membrane Integrity.
Stokes JM; French S; Ovchinnikova OG; Bouwman C; Whitfield C; Brown ED
Cell Chem Biol; 2016 Feb; 23(2):267-277. PubMed ID: 26853624
[TBL] [Abstract][Full Text] [Related]
40. [Infections of vancomycin resistant enterococci (VRE) and Staphylococcus aureus (VRSA)].
Kuwahara K; Hanaki H; Hiramatsu K
Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):182-5. PubMed ID: 10088368
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
